ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 89 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,525,856 | -30.8% | 657,280 | -37.9% | 0.30% | -20.3% |
| Q2 2023 | $10,881,380 | +42.4% | 1,058,500 | +7.0% | 0.38% | +49.6% |
| Q1 2023 | $7,638,940 | +1.1% | 989,500 | -3.8% | 0.25% | +54.9% |
| Q4 2022 | $7,557,270 | +5.1% | 1,028,200 | +3.0% | 0.16% | +12.3% |
| Q3 2022 | $7,190,000 | -15.4% | 998,600 | +0.0% | 0.15% | -25.1% |
| Q2 2022 | $8,498,000 | -21.5% | 998,565 | -17.3% | 0.20% | -13.3% |
| Q1 2022 | $10,827,000 | -41.9% | 1,207,000 | -10.3% | 0.22% | -43.0% |
| Q4 2021 | $18,628,000 | -9.6% | 1,345,000 | -30.4% | 0.40% | -13.6% |
| Q3 2021 | $20,614,000 | +53.2% | 1,932,000 | +29.2% | 0.46% | +25.5% |
| Q2 2021 | $13,455,000 | -16.0% | 1,495,000 | -1.1% | 0.36% | -17.6% |
| Q1 2021 | $16,017,000 | +1.9% | 1,511,000 | +21.1% | 0.44% | -13.5% |
| Q4 2020 | $15,725,000 | +120.9% | 1,248,000 | +54.1% | 0.51% | +54.8% |
| Q3 2020 | $7,120,000 | – | 810,000 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |